These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17456722)

  • 1. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
    Flotho C; Coustan-Smith E; Pei D; Cheng C; Song G; Pui CH; Downing JR; Campana D
    Blood; 2007 Aug; 110(4):1271-7. PubMed ID: 17456722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
    Flotho C; Coustan-Smith E; Pei D; Iwamoto S; Song G; Cheng C; Pui CH; Downing JR; Campana D
    Blood; 2006 Aug; 108(3):1050-7. PubMed ID: 16627760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting outcome in childhood acute lymphoblastic leukemia using gene expression profiling: prognostication or protocol selection?
    Catchpoole D; Guo D; Jiang H; Biesheuvel C
    Blood; 2008 Feb; 111(4):2486-7; author reply 2487-8. PubMed ID: 18263786
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
    Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
    Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia.
    Stanulla M; Schrauder A
    Haematologica; 2009 Jun; 94(6):748-52. PubMed ID: 19483150
    [No Abstract]   [Full Text] [Related]  

  • 11. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
    Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia.
    Choi J; Hwang YK; Sung KW; Lee SH; Yoo KH; Jung HL; Koo HH; Kim HJ; Kang HJ; Shin HY; Ahn HS
    Blood; 2007 Jan; 109(2):471-7. PubMed ID: 16990595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of MDR1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy.
    Fedasenka UU; Shman TV; Savitski VP; Belevcev MV
    Exp Oncol; 2008 Sep; 30(3):248-52. PubMed ID: 18806751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
    Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
    Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.
    Chen JS; Coustan-Smith E; Suzuki T; Neale GA; Mihara K; Pui CH; Campana D
    Blood; 2001 Apr; 97(7):2115-20. PubMed ID: 11264179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.
    Rzepiel A; Kutszegi N; Gézsi A; Sági JC; Egyed B; Péter G; Butz H; Nyírő G; Müller J; Kovács GT; Szalai C; Semsei ÁF; Erdélyi DJ
    J Transl Med; 2019 Nov; 17(1):372. PubMed ID: 31727091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
    Stow P; Key L; Chen X; Pan Q; Neale GA; Coustan-Smith E; Mullighan CG; Zhou Y; Pui CH; Campana D
    Blood; 2010 Jun; 115(23):4657-63. PubMed ID: 20304809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.